Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

<i>Coot</i> : model-building tools for molecular graphics

Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · see citing works

Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features

Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320 · see citing works

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,671 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Synthesis of Proteins by Native Chemical Ligation

Dawson, P. E., Muir, T. W., Clark‐Lewis, I., & Kent, S. B. H. (1994) · Science · doi:10.1126/science.7973629 · Cited by 4,142 · see citing works

How to measure and predict the molar absorption coefficient of a protein

Pace, C., Vajdos, F., Fee, L. R., Grimsley, G., & Gray, T. (1995) · Protein Science · doi:10.1002/pro.5560041120 · Cited by 3,924 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

Likelihood-enhanced fast rotation functions

Storoni, L. C., McCoy, A. J., & Read, R. J. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444903028956 · Cited by 1,177 · see citing works

Synthesis of Native Proteins by Chemical Ligation

Dawson, P. E., & Kent, S. B. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.923 · Cited by 1,084 · see citing works

Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies

Massova, I., & Kollman, P. A. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990935j · Cited by 778 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652 · see citing works

MDMX: a novel p53‐binding protein with some functional properties of MDM2.

Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

Cell-penetrating and cell-targeting peptides in drug delivery

Vivès, É., Schmidt, J., & Pèlegrin, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.03.001 · Cited by 442 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation

Stommel, J. M., & Wahl, G. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600145 · Cited by 386 · see citing works

Molecular Mechanism of the Interaction between MDM2 and p53

Schön, O., Friedler, A., Bycroft, M., Freund, S. M. V., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00852-5 · Cited by 349 · see citing works

Tumor-suppressor p53: implications for tumor development and prognosis.

Kirsch, D. G., & Kastan, M. B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3158 · Cited by 301 · see citing works

Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells <i>in vivo</i>

Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., & Marine, J.-C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508476103 · Cited by 260 · see citing works

Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn

Böttger, A., Böttger, V., Garcı́a-Echeverrı́a, C., Chêne, P., Hochkeppel, H. K., Sampson, W. R., Ang, K. H., Howard, S. F., Picksley, S. M., & Lane, D. P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1078 · Cited by 251 · see citing works

MDM2 promotes ubiquitination and degradation of MDMX

Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246 · see citing works

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238 · see citing works

MDMX: from bench to bedside

Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228 · see citing works

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 214 · see citing works

MdmX Protects p53 from Mdm2-Mediated Degradation

Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211 · cited 1× · see citing works

A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network

Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199 · cited 1× · see citing works

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

Popowicz, G. M., Czarna, A., & Holak, T. A. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 195 · see citing works

Targeting protein–protein interactions: Lessons from p53/MDM2

Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 186 · see citing works

Identification of novel mdm2 binding peptides by phage display.

Böttger, V., Böttger, A., Howard, S. F., Picksley, S. M., Chêne, P., Garcı́a-Echeverrı́a, C., Hochkeppel, H. K., & Lane, D. P. (1996) · PubMed · Cited by 182 · see citing works

DNA damage-induced MDMX degradation is mediated by MDM2

Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K. C., & Yuan, Z.-M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308295200 · Cited by 163 · see citing works

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2

de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143 · see citing works

Molecular Basis for the Inhibition of p53 by Mdmx

Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131 · see citing works

Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction

Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129 · see citing works

Multiple Peptide Conformations Give Rise to Similar Binding Affinities: Molecular Simulations of p53-MDM2

Dastidar, S. G., Lane, D. P., & Verma, C. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804289g · Cited by 87 · see citing works

Miniature Protein Inhibitors of the p53–hDM2 Interaction

Kritzer, J. A., Zutshi, R., Cheah, M. T., Ran, F. A., Webman, R. B., Wongjirad, T. M., & Schepartz, A. (2006) · ChemBioChem · doi:10.1002/cbic.200500324 · Cited by 87 · see citing works

Turning a Scorpion Toxin into an Antitumor Miniprotein

Li, C., Liu, M., Monbo, J., Zou, G., Li, C., Yuan, W., Zella, D., Lu, W., & Lu, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8042036 · Cited by 75 · see citing works

Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes

Kallen, J. A., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 72 · see citing works

Determinants of Specificity of MDM2 for the Activation Domains of p53 and p65: Proline27 Disrupts the MDM2-Binding Motif of p53

Zondlo, S. C., Lee, A. E., & Zondlo, N. J. (2006) · Biochemistry · doi:10.1021/bi060309g · Cited by 65 · see citing works

Thermodynamics of p53 Binding to hdm2(1–126): Effects of Phosphorylation and p53 Peptide Length

Lai, Z., Auger, K. R., Manubay, C. M., & Copeland, R. A. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1998 · Cited by 64 · see citing works

Crystallographic Analysis of an 8-mer p53 Peptide Analogue Complexed with MDM2

Sakurai, K., Schubert, C., & Kahne, D. E. (2006) · Journal of the American Chemical Society · doi:10.1021/ja063102j · Cited by 58 · see citing works

Structure of Human MDM4 N-Terminal Domain Bound to a Single-Domain Antibody

Yu, G. W., Vaysburd, M., Allen, M. D., Settanni, G., & Fersht, A. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.043 · Cited by 12 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Awakening guardian angels: drugging the p53 pathway

Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Structure‐Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes

Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 718 · see citing works

Novel trends in high-throughput screening

Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 690 · see citing works

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 666 · see citing works

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449 · see citing works

The MDM2-p53 pathway revisited

Nag, S. A., Jiangjiang, Q., Kalkunte, S. S., Ming-hai, W., & Zhang, R. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

New Modalities for Challenging Targets in Drug Discovery

Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382 · see citing works

The Tumor Suppressor p53: From Structures to Drug DiscoveryPreprint

Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 356 · see citing works

Targeting Transcription Factors for Cancer Treatment

Lambert, M., Jambon, S., Depauw, S., & David‐Cordonnier, M. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 351 · see citing works

Peptide therapeutics: Targeting the undruggable space

Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348 · see citing works

Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment

Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., Wei, T., Cao, W., Zou, G., & Liang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.058 · Cited by 315 · see citing works

The Roles of MDM2 and MDMX in Cancer

Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 294 · see citing works

Hydrocarbon Stapled Peptides as Modulators of Biological Function

Cromm, P. M., Spiegel, J., & Grossmann, T. N. (2015) · ACS Chemical Biology · doi:10.1021/cb501020r · Cited by 289 · see citing works

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 284 · see citing works

Structure of the Stapled p53 Peptide Bound to Mdm2

Baek, S., Kutchukian, P. S., Verdine, G. L., Huber, R., Holak, T. A., Lee, K. W., & Popowicz, G. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2090367 · Cited by 259 · see citing works

Phage display—A powerful technique for immunotherapy

Bazan, J., Całkosiński, I., & Gamian, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21703 · Cited by 253 · see citing works

p53-based Cancer TherapyPreprint

Lane, D. P., Cheok, C. F., & Laı́n, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 244 · see citing works

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A. G., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 233 · see citing works

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230 · see citing works

p53 as a target for the treatment of cancer

Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J. P., O’Connor, D. P., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 230 · see citing works

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 229 · see citing works

Phage Display in Molecular Imaging and Diagnosis of Cancer

Deutscher, S. L. (2010) · Chemical Reviews · doi:10.1021/cr900317f · Cited by 215 · see citing works

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206 · see citing works

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · see citing works

Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein–Protein Interactions

Cardote, T. A. F., & Ciulli, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500450 · Cited by 189 · see citing works

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173 · see citing works

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious

Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 166 · see citing works

Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations

Paul, F., Wehmeyer, C., Abualrous, E. T., Wu, H., Crabtree, M., Schöneberg, J., Clarke, J., Freund, C., Weikl, T. R., & Noé, F. (2017) · Nature Communications · doi:10.1038/s41467-017-01163-6 · Cited by 158 · see citing works

Antibody Engineering for Pursuing a Healthier Future

Saeed, A. F. U. H., Wang, R., Ling, S., & Wang, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00495 · Cited by 154 · see citing works

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 153 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Ultra-large chemical libraries for the discovery of high-affinity peptide binders

Quartararo, A. J., Gates, Z. P., Somsen, B. A., Hartrampf, N., Ye, X., Shimada, A., Kajihara, Y., Ottmann, C., & Pentelute, B. L. (2020) · Nature Communications · doi:10.1038/s41467-020-16920-3 · Cited by 154 · see citing works

Trapping Moving Targets with Small Molecules

Lee, G., & Craik, C. S. (2009) · Science · doi:10.1126/science.1169378 · Cited by 145 · see citing works

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 146 · see citing works

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development

Guerlavais, V., Sawyer, T. K., Carvajal, L. A., Chang, Y. S., Graves, B. J., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K. E., Darłak, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00623 · Cited by 145 · see citing works

Reactivation of p53: from peptides to small molecules

Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 135 · see citing works

Self-Assembled Peptide–Lanthanide Nanoclusters for Safe Tumor Therapy: Overcoming and Utilizing Biological Barriers to Peptide Drug Delivery

Yan, J., He, W., Yan, S., Niu, F., Liu, T., Ma, B., Shao, Y., Yan, Y., Yang, G., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00081 · Cited by 133 · see citing works

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508416 · Cited by 126 · see citing works

Novel Pyrrolopyrimidine-Based α-Helix Mimetics: Cell-Permeable Inhibitors of Protein−Protein Interactions

Lee, J. H., Zhang, Q., Jo, S., Chai, S. C., Oh, M., Im, W., Lu, H., & Lim, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja108230s · Cited by 126 · see citing works

Mirror-image protein and peptide drug discovery through mirror-image phage display

Qi, Y., Zheng, J., & Liu, L. (2024) · Chem · doi:10.1016/j.chempr.2024.06.004 · Cited by 122 · see citing works

Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding

Andrésen, C., Helander, S., Lemak, A. S., Farès, C., Csizmók, V., Carlsson, J., Penn, L. Z., Forman-Kay, J. D., Arrowsmith, C. H., Lundström, P., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks263 · Cited by 119 · see citing works

A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction

Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115 · see citing works

Targeting intrinsically disordered proteins involved in cancer

Santofimia‐Castaño, P., Rizzuti, B., Xia, Y., Abián, O., Peng, L., Velázquez‐Campoy, A., Neira, J. L., & Iovanna, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03347-3 · Cited by 110 · see citing works

Synthesis and applications of mirror-image proteins

Harrison, K., Mackay, A. S., Kambanis, L., Maxwell, J. W. C., & Payne, R. J. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00493-y · Cited by 104 · see citing works

How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures

Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 100 · see citing works

Strukturbasierte Entwicklung von Protein‐Protein‐Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden

Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie · doi:10.1002/ange.201412070 · Cited by 90 · see citing works

Enhanced cellular uptake and nuclear accumulation of drug-peptide nanomedicines prepared by enzyme-instructed self-assembly

Liang, C., Yan, X., Zhang, R., Xu, T., Zheng, D., Tan, Z., Chen, Y., Gao, Z., Wang, L., Li, X., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.028 · Cited by 89 · see citing works

Rational Improvement of the Affinity and Selectivity of Integrin Binding of Grafted Lasso Peptides

Hegemann, J. D., Simone, M. D., Zimmermann, M., Knappe, T. A., Xie, X., Leva, F. S. D., Marinelli, L., Novellino, E., Stefan Zahler, A., Kessler, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5004478 · Cited by 89 · see citing works

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Ma, B., Fan, Y., Zhang, D., Wei, Y., Jian, Y., Liu, D., Wang, Z., Gao, Y., Ma, J., Chen, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202201859 · Cited by 86 · see citing works

Enhanced Suppression of a Protein–Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an N-Acyl-N-alkyl Sulfonamide Warhead

Ueda, T., Tamura, T., Kawano, M., Shiono, K., Hóbor, F., Wilson, A. J., & Hamachi, I. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00703 · Cited by 84 · see citing works

A Versatile Platform to Analyze Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real Time

Li, Y., Rodewald, L. W., Hoppmann, C., Wong, E. T., Lebreton, S., Šafář, P., Pátek, M., Wang, L., Wertman, K. F., & Wahl, G. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.058 · Cited by 83 · see citing works

Targeting p53-MDM2-MDMX Loop for Cancer Therapy

Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 83 · see citing works

Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide

Dougherty, P. G., Wen, J., Pan, X., Koley, A., Ren, J.-G., Sahni, A., Basu, R., Salim, H., Kubi, G. A., Qian, Z., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00456 · Cited by 83 · see citing works

An Ultrahigh Affinity d -Peptide Antagonist Of MDM2

Zhan, C., Zhao, L., Wei, X., Wu, X., Chen, X., Yuan, W., Lu, W., Pazgier, M., & Lu, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005465 · Cited by 80 · see citing works

In-solution enrichment identifies peptide inhibitors of protein–protein interactions

Touti, F., Gates, Z. P., Bandyopadhyay, A., Lautrette, G., & Pentelute, B. L. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0245-2 · Cited by 81 · see citing works

Therapeutic stapled peptides: Efficacy and molecular targets

Li, Y., Wu, M., Fu, Y., Xue, J., Yuan, F., Qu, T., Rissanou, A. N., Wang, Y., Li, X., & Hu, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107137 · Cited by 85 · see citing works

Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry

Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79 · see citing works

Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53

Li, C., Pazgier, M., Liu, M., Lu, W., & Lu, W. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904550 · Cited by 79 · see citing works

Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer

Mabonga, L., & Kappo, A. P. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09831-5 · Cited by 78 · see citing works

Computed Binding of Peptides to Proteins with MELD-Accelerated Molecular Dynamics

Morrone, J. A., Pérez, A., MacCallum, J. L., & Dill, K. A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00977 · Cited by 75 · see citing works

Unnatural helical peptidic foldamers as protein segment mimics

Sang, P., & Cai, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00395c · Cited by 76 · see citing works

A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings

Chen, J., Wang, J., Zhu, W., & Li, G. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9693-z · Cited by 75 · see citing works

Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy

Niu, F., Yan, J., Ma, B., Li, S., Shao, Y., He, P., Zhang, W., He, W., Ma, P. X., & Lu, W. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.025 · Cited by 72 · see citing works

Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design

Li, X., Tolbert, W. D., Hu, H., Gohain, N., Zou, Y., Niu, F., He, W., Yuan, W., Su, J., Pazgier, M., et al. (2018) · Chemical Science · doi:10.1039/c8sc03275k · Cited by 71 · see citing works

Functionalized Peptide-Based Nanoparticles for Targeted Cancer Nanotherapeutics: A State-of-the-Art Review

Sharma, R., Borah, S. J., Bhawna, Kumar, S., Gupta, A., Singh, P., Goel, V. K., Kumar, R., & Kumar, V. (2022) · ACS Omega · doi:10.1021/acsomega.2c03974 · Cited by 71 · see citing works

Small molecules targeting protein–protein interactions for cancer therapy

Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71 · see citing works

Designing helical peptide inhibitors of protein–protein interactions

Araghi, R. R., & Keating, A. E. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.04.001 · Cited by 64 · see citing works

Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73

Zdzalik, M., Pustelny, K., Kędracka–Krok, S., Huben, K., Pęcak, A., Władyka, B., Jankowski, S., Dubin, A., Potempa, J., & Dubin, G. (2010) · Cell Cycle · doi:10.4161/cc.9.22.13871 · Cited by 65 · see citing works

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression

Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 64 · see citing works

Mirror image proteins

Zhao, L., & Lu, W. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.09.019 · Cited by 62 · see citing works

Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions

Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61 · see citing works

A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation

Chen, X., Tai, L., Gao, J., Qian, J., Zhang, M., Li, B., Xie, C., Lu, L., Lu, W., & Lu, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.061 · Cited by 59 · see citing works

Expanding the horizons of targeted protein degradation: A non-small molecule perspective

Huang, X., Wu, F., Ye, J., Wang, L., Wang, X., Li, X., & He, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.010 · Cited by 58 · see citing works

When the guardian sleeps: Reactivation of the p53 pathway in cancer

Merkel, O., Taylor, N., Prutsch, N., Staber, P. B., Moriggl, R., Turner, S. D., & Kenner, L. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.003 · Cited by 54 · see citing works

Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy

DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 57 · see citing works

Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties

Partridge, A. W., Kaan, H. Y. K., Juang, Y.-C. A., Sadruddin, A., Lim, S., Brown, C. J., Ng, S., Thean, D., Ferrer, F. J., Johannes, C. W., et al. (2019) · Molecules · doi:10.3390/molecules24122292 · Cited by 57 · see citing works

On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53

Bista, M., Smithson, D., Pecak, A., Salinas, G., Pustelny, K., Min, J., Pirog, A., Finch, K., Zdzalik, M., Waddell, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037518 · Cited by 58 · see citing works

A novel peptide stapling strategy enables the retention of ring-closing amino acid side chains for the Wnt/β-catenin signalling pathway

Wu, Y., Li, Y., Li, X., Zou, Y., Liao, H., Liu, L., Chen, Y., Bierer, D. E., & Hu, H. (2017) · Chemical Science · doi:10.1039/c7sc02420g · Cited by 56 · see citing works

Discovery of PSMA-specific peptide ligands for targeted drug delivery

Jin, W., Qin, B. Y., Chen, Z., Liu, H., Barve, A. J., & Cheng, K. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.048 · Cited by 55 · see citing works

Molecular Simulations Identify Binding Poses and Approximate Affinities of Stapled α-Helical Peptides to MDM2 and MDMX

Morrone, J. A., Pérez, A., Deng, Q., Ha, S., Holloway, M. K., Sawyer, T. K., Sherborne, B. S., Brown, F. K., & Dill, K. A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00978 · Cited by 54 · see citing works

Using Peptides to Study Protein–Protein Interactions

Benyamini, H., & Friedler, A. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.196 · Cited by 51 · see citing works

Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy

He, W., Yan, J., Sui, F., Wang, S., Su, X., Qu, Y., Yang, Q., Guo, H., Ji, M., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b07079 · Cited by 51 · see citing works

A guide to the optogenetic regulation of endogenous molecules

Manoilov, K. Y., Verkhusha, V. V., & Shcherbakova, D. M. (2021) · Nature Methods · doi:10.1038/s41592-021-01240-1 · Cited by 51 · see citing works

Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy

Zhan, C., Li, C., Wei, X., Lu, W., & Lu, W. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.025 · Cited by 49 · see citing works

Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined

Zhan, C., Varney, K. M., Yuan, W., Zhao, L., & Lu, W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301255n · Cited by 49 · see citing works

Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation

Chen, J., Wang, J., Zhang, Q., Chen, K., & Zhu, W. (2015) · Scientific Reports · doi:10.1038/srep17421 · Cited by 49 · see citing works

Target-Specific De Novo Peptide Binder Design with DiffPepBuilder

Wang, F., Wang, Y. X., Feng, L., Zhang, C., & Lai, L. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00975 · Cited by 52 · see citing works

Casein Kinase 1α Regulates an MDMX Intramolecular Interaction To Stimulate p53 Binding

Wu, S., Chen, L., Becker, A., Schönbrunn, E., & Chen, J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-12 · Cited by 48 · see citing works

Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions

Zhang, S., Lou, J., Li, Y., Zhou, F., Yan, Z., Lyu, X., & Zhao, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00940 · Cited by 47 · see citing works

Directed Disulfide Pairing and Folding of Peptides for the De Novo Development of Multicyclic Peptide Libraries

Lu, S., Wu, Y., Li, J., Meng, X., Hu, C., Zhao, Y., & Wu, C. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c06044 · Cited by 46 · see citing works

Structural Basis for α‐Helix Mimicry and Inhibition of Protein–Protein Interactions with Oligourea Foldamers

Cussol, L., Mauran, L., Buratto, J., Belorusova, A. Y., Neuville, M., Ősz, J., Fribourg, S., Frémaux, J., Dolain, C., Goudreau, S. R., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008992 · Cited by 46 · see citing works

Differences in the transactivation domains of p53 family members: a computational study

Mavinahalli, J., Madhumalar, A., Beuerman, R. W., Lane, D. P., & Verma, C. S. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-s1-s5 · Cited by 46 · see citing works

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 48 · see citing works

Free Energy Profile and Kinetics of Coupled Folding and Binding of the Intrinsically Disordered Protein p53 with MDM2

Zou, R., Zhou, Y., Wang, Y., Kuang, G., Ågren, H., Wu, J., & Tu, Y. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00920 · Cited by 45 · see citing works

Recent Advances in Peptide-Based Approaches for Cancer Treatment

Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 44 · see citing works

A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics

Yan, J., Ji, F., Yan, S., You, W., Ma, F., Li, F., Huang, Y., Liu, W., & He, W. (2020) · Theranostics · doi:10.7150/thno.47243 · Cited by 44 · see citing works

A Cyclized Helix‐Loop‐Helix Peptide as a Molecular Scaffold for the Design of Inhibitors of Intracellular Protein–Protein Interactions by Epitope and Arginine Grafting

Fujiwara, D., Kitada, H., Oguri, M., Nishihara, T., Michigami, M., Shiraishi, K., Yuba, E., Nakase, I., Im, H., Cho, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201603230 · Cited by 44 · see citing works

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 146 · see citing works

Structural Basis for Inhibition of the MDM2:p53 Interaction by an Optimized MDM2-Binding Peptide Selected with mRNA Display

Nagata, T., Shirakawa, K., Kobayashi, N., Shiheido, H., Tabata, N., Sakuma-Yonemura, Y., Horisawa, K., Katahira, M., Doi, N., & Yanagawa, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109163 · Cited by 20 · see citing works

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173 · see citing works

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 44 · see citing works

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

Czarna, A., Popowicz, G. M., Pęcak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 99 · see citing works